Cargando…

Present Status, Limitations and Future Directions of Treatment Strategies Using Fucoidan-Based Therapies in Bladder Cancer

SIMPLE SUMMARY: Prognosis of bladder cancer patients is often poor despite various intensive treatments are performed. Therefore, many investigators pay attention to the efficacy of natural product-based treatments to avoid additional adverse events in these patients. Here, we review the anti-cancer...

Descripción completa

Detalles Bibliográficos
Autores principales: Miyata, Yasuyoshi, Matsuo, Tomohiro, Ohba, Kojiro, Mitsunari, Kensuke, Mukae, Yuta, Otsubo, Asato, Harada, Junki, Matsuda, Tsuyoshi, Kondo, Tsubasa, Sakai, Hideki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7765304/
https://www.ncbi.nlm.nih.gov/pubmed/33333858
http://dx.doi.org/10.3390/cancers12123776
_version_ 1783628460413943808
author Miyata, Yasuyoshi
Matsuo, Tomohiro
Ohba, Kojiro
Mitsunari, Kensuke
Mukae, Yuta
Otsubo, Asato
Harada, Junki
Matsuda, Tsuyoshi
Kondo, Tsubasa
Sakai, Hideki
author_facet Miyata, Yasuyoshi
Matsuo, Tomohiro
Ohba, Kojiro
Mitsunari, Kensuke
Mukae, Yuta
Otsubo, Asato
Harada, Junki
Matsuda, Tsuyoshi
Kondo, Tsubasa
Sakai, Hideki
author_sort Miyata, Yasuyoshi
collection PubMed
description SIMPLE SUMMARY: Prognosis of bladder cancer patients is often poor despite various intensive treatments are performed. Therefore, many investigators pay attention to the efficacy of natural product-based treatments to avoid additional adverse events in these patients. Here, we review the anti-cancer effects of fucoidan-based treatments and the protective effects against cancer-related disorders and cisplatin-induced toxicities. ABSTRACT: Bladder cancer (BC) is a common urological cancer, with poor prognosis for advanced/metastatic stages. Various intensive treatments, including radical cystectomy, chemotherapy, immune therapy, and radiotherapy are commonly used for these patients. However, these treatments often cause complications and adverse events. Therefore, researchers are exploring the efficacy of natural product-based treatment strategies in BC patients. Fucoidan, derived from marine brown algae, is recognized as a multi-functional and safe substrate, and has been reported to have anti-cancer effects in various types of malignancies. Additionally, in vivo and in vitro studies have reported the protective effects of fucoidan against cancer-related cachexia and chemotherapeutic agent-induced adverse events. In this review, we have introduced the anti-cancer effects of fucoidan extracts in BC and highlighted its molecular mechanisms. We have also shown the anti-cancer effects of fucoidan therapy with conventional chemotherapeutic agents and new treatment strategies using fucoidan-based nanoparticles in various malignancies. Moreover, apart from the improvement of anti-cancer effects by fucoidan, its protective effects against cancer-related disorders and cisplatin-induced toxicities have been introduced. However, the available information is insufficient to conclude the clinical usefulness of fucoidan-based treatments in BC patients. Therefore, we have indicated the aspects that need to be considered regarding fucoidan-based treatments and future directions for the treatment of BC.
format Online
Article
Text
id pubmed-7765304
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-77653042020-12-27 Present Status, Limitations and Future Directions of Treatment Strategies Using Fucoidan-Based Therapies in Bladder Cancer Miyata, Yasuyoshi Matsuo, Tomohiro Ohba, Kojiro Mitsunari, Kensuke Mukae, Yuta Otsubo, Asato Harada, Junki Matsuda, Tsuyoshi Kondo, Tsubasa Sakai, Hideki Cancers (Basel) Review SIMPLE SUMMARY: Prognosis of bladder cancer patients is often poor despite various intensive treatments are performed. Therefore, many investigators pay attention to the efficacy of natural product-based treatments to avoid additional adverse events in these patients. Here, we review the anti-cancer effects of fucoidan-based treatments and the protective effects against cancer-related disorders and cisplatin-induced toxicities. ABSTRACT: Bladder cancer (BC) is a common urological cancer, with poor prognosis for advanced/metastatic stages. Various intensive treatments, including radical cystectomy, chemotherapy, immune therapy, and radiotherapy are commonly used for these patients. However, these treatments often cause complications and adverse events. Therefore, researchers are exploring the efficacy of natural product-based treatment strategies in BC patients. Fucoidan, derived from marine brown algae, is recognized as a multi-functional and safe substrate, and has been reported to have anti-cancer effects in various types of malignancies. Additionally, in vivo and in vitro studies have reported the protective effects of fucoidan against cancer-related cachexia and chemotherapeutic agent-induced adverse events. In this review, we have introduced the anti-cancer effects of fucoidan extracts in BC and highlighted its molecular mechanisms. We have also shown the anti-cancer effects of fucoidan therapy with conventional chemotherapeutic agents and new treatment strategies using fucoidan-based nanoparticles in various malignancies. Moreover, apart from the improvement of anti-cancer effects by fucoidan, its protective effects against cancer-related disorders and cisplatin-induced toxicities have been introduced. However, the available information is insufficient to conclude the clinical usefulness of fucoidan-based treatments in BC patients. Therefore, we have indicated the aspects that need to be considered regarding fucoidan-based treatments and future directions for the treatment of BC. MDPI 2020-12-15 /pmc/articles/PMC7765304/ /pubmed/33333858 http://dx.doi.org/10.3390/cancers12123776 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Miyata, Yasuyoshi
Matsuo, Tomohiro
Ohba, Kojiro
Mitsunari, Kensuke
Mukae, Yuta
Otsubo, Asato
Harada, Junki
Matsuda, Tsuyoshi
Kondo, Tsubasa
Sakai, Hideki
Present Status, Limitations and Future Directions of Treatment Strategies Using Fucoidan-Based Therapies in Bladder Cancer
title Present Status, Limitations and Future Directions of Treatment Strategies Using Fucoidan-Based Therapies in Bladder Cancer
title_full Present Status, Limitations and Future Directions of Treatment Strategies Using Fucoidan-Based Therapies in Bladder Cancer
title_fullStr Present Status, Limitations and Future Directions of Treatment Strategies Using Fucoidan-Based Therapies in Bladder Cancer
title_full_unstemmed Present Status, Limitations and Future Directions of Treatment Strategies Using Fucoidan-Based Therapies in Bladder Cancer
title_short Present Status, Limitations and Future Directions of Treatment Strategies Using Fucoidan-Based Therapies in Bladder Cancer
title_sort present status, limitations and future directions of treatment strategies using fucoidan-based therapies in bladder cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7765304/
https://www.ncbi.nlm.nih.gov/pubmed/33333858
http://dx.doi.org/10.3390/cancers12123776
work_keys_str_mv AT miyatayasuyoshi presentstatuslimitationsandfuturedirectionsoftreatmentstrategiesusingfucoidanbasedtherapiesinbladdercancer
AT matsuotomohiro presentstatuslimitationsandfuturedirectionsoftreatmentstrategiesusingfucoidanbasedtherapiesinbladdercancer
AT ohbakojiro presentstatuslimitationsandfuturedirectionsoftreatmentstrategiesusingfucoidanbasedtherapiesinbladdercancer
AT mitsunarikensuke presentstatuslimitationsandfuturedirectionsoftreatmentstrategiesusingfucoidanbasedtherapiesinbladdercancer
AT mukaeyuta presentstatuslimitationsandfuturedirectionsoftreatmentstrategiesusingfucoidanbasedtherapiesinbladdercancer
AT otsuboasato presentstatuslimitationsandfuturedirectionsoftreatmentstrategiesusingfucoidanbasedtherapiesinbladdercancer
AT haradajunki presentstatuslimitationsandfuturedirectionsoftreatmentstrategiesusingfucoidanbasedtherapiesinbladdercancer
AT matsudatsuyoshi presentstatuslimitationsandfuturedirectionsoftreatmentstrategiesusingfucoidanbasedtherapiesinbladdercancer
AT kondotsubasa presentstatuslimitationsandfuturedirectionsoftreatmentstrategiesusingfucoidanbasedtherapiesinbladdercancer
AT sakaihideki presentstatuslimitationsandfuturedirectionsoftreatmentstrategiesusingfucoidanbasedtherapiesinbladdercancer